Navigation Links
GenTel licenses next generation cancer research

Madison, Wis. - Recent biochemical research into certain forms of cancer has focused on disease-related changes in the protein composition of blood. As these studies progress, significant lines of inquiry will examine not only the protein changes induced by cancer but changes in the sugar molecules that naturally attach to those proteins.

In the serum of pancreatic cancer patients,......

Full article >>> roteins (such as antibodies) in a process called glycosylation. This process occurs as part of biosynthesis and is an important determinant of protein function.

Changes in glycosylation are thought to play roles in certain disease processes.

GenTel's technology modifies the normal sugar molecules associated with antibodies printed on GenTel's arrays so that they are no longer rea......

Full article >>> ollow.

Added Nelson: "We're going to make this available to a much broader audience. We're going to expand it to look at prostate and other cancers."

The market for tumor serum analyte in-vitro diagnostic tests is approximately $1 billion per year worldwide, Negm said. Although nobody has an exact number on the glycosylation segment of that market, Negm believes that GenTel's fir......

Full article >>>
'"/> By Chris Fleissner 08/17/06

Related biology technology :

1. GenTel acquires GlaxoSmithKline chip platform
2. New angel capital centered on GenTel agreement with big pharma
3. GenTel to distribute cancer research tool
4. GenTel gets federal grant to develop allergy test
5. Madisons GenTel partners with Taiwan firm
6. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
7. GenTel BioSurfaces launches new assay platform
8. GenTel will sell Dutch firms biomolecule labeling technology
9. Bone Care, GenTel, MyWeather
10. GenTel receives $250,000 state loan
11. GenTel claims $900,000 in federal grants this year for biochip research
Post Your Comments:

(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... ... genomics company uBiome, were featured on AngelList early in their initial angel funding ... an AngelList syndicate for individuals looking to make early stage investments in the ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... -- --> --> ... Market by Product & Services (Primer, Probe, Custom Oligos, ... End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - Global ... expected to reach USD 1,918.6 Million by 2020 from ... 10.1% during the forecast period. Browse 183 ...
(Date:11/24/2015)... Ltd. (OTCQB: TIKRF) today announced that its Annual General Meeting of Shareholders ... Israel time, at the law offices of Goldfarb Seligman ... Floor, Tel Aviv, Israel . ... to the Board of Directors; , election of Liat ... an amendment to certain terms of options granted to our Chief Executive ...
Breaking Biology Technology:
(Date:11/17/2015)... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and ... of broadly enabling, pressure cycling technology ("PCT")-based sample preparation ... it has received gross proceeds of $745,000 from an ... "Offering"), increasing the total amount raised to date in ... are expected in the near future. ...
(Date:11/12/2015)... BOSTON , Nov. 12, 2015  A golden ... for Duchenne muscular dystrophy (DMD) has provided a new ... Boston Children,s Hospital, the Broad Institute of MIT and ... Brazil . Cell, ... some dogs "escape" the disease,s effects. The Boston Children,s ...
(Date:11/12/2015)... 2015   Growing need for low-cost, easy ... been paving the way for use of biochemical ... analytes in clinical, agricultural, environmental, food and defense ... in medical applications, however, their adoption is increasing ... continuous emphasis on improving product quality and growing ...
Breaking Biology News(10 mins):